Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor

STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo

(2014) Aws Alshamsan et al.   Translational Oncology

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

Abstract B89: The effects of raf kinase inhibition with either sorafenib or PLX-4720 on Mcl-1 expression and cytotoxicity alone and in combination with ABT-737 in melanoma cell lines

(2012) L. M. Curtis et al.   MOLECULAR CANCER THERAPEUTICS

Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma

(2011) Trine O. Jensen et al.   CANCER

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

BRAF as therapeutic target in melanoma

(2010) Claudia Wellbrock et al.   BIOCHEMICAL PHARMACOLOGY

STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma

(2010) A Horiguchi et al.   BRITISH JOURNAL OF CANCER

Akt3-Mediated Resistance to Apoptosis in B-RAF-Targeted Melanoma Cells

(2010) Y. Shao et al.   CANCER RESEARCH

IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence

(2010) Lyndee L. Scurr et al.   CELL

Inhibition of p-STAT3 Enhances IFN-  Efficacy against Metastatic Melanoma in a Murine Model

(2010) L. Y. Kong et al.   CLINICAL CANCER RESEARCH

Oncogenic B-RAFV600E Promotes Anchorage-Independent Survival of Human Melanocytes

(2010) Therese M. Becker et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells

(2010) Li Lin et al.   Molecular Cancer

The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity

(2010) Matthew A Bill et al.   Molecular Cancer

Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS

(2010) C C Jiang et al.   Cell Death & Disease

B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma

(2010) Cynthia Shepherd et al.   Current Oncology Reports

Signal Transducer and Activator of Transcription-3, Inflammation, and Cancer

(2009) Bharat B. Aggarwal et al.   Annals of the New York Academy of Sciences

LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model

(2009) B Fuh et al.   BRITISH JOURNAL OF CANCER

BRAF Signaling and Targeted Therapies in Melanoma

(2009) Nathalie Dhomen et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Oncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors

(2009) Sebastian Haferkamp et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis

(2009) K. Boisvert-Adamo et al.   MOLECULAR CANCER RESEARCH

The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling

(2009) L Lin et al.   ONCOGENE

Mcl-1 is a potential therapeutic target in multiple types of cancer

(2008) C. Akgul   CELLULAR AND MOLECULAR LIFE SCIENCES

Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells

(2008) R. Buettner et al.   MOLECULAR CANCER RESEARCH